Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma
- PMID: 1834122
- DOI: 10.1016/0277-5379(91)90140-9
Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma
Abstract
Effects of the vasoconstrictor angiotensin II on tumour microvascular perfusion and oxygenation were examined in the murine SCCVII carcinoma grown subcutaneously in C3H/He mice. Angiotensin II infusion (2 micrograms/kg/min) caused an increase in mouse arterial blood pressure from 85 (2) mm Hg (mean, S.D.) to 112 (7) mm Hg. During drug infusion, tumour red blood cell (RBC) flow (measured by laser doppler flowmetry) increased 206 (50%) (P less than 0.001) in unanaesthetised animals and 305 (90%) (P less than 0.001) in mice immobilised with ketamine and diazepam. As assessed using a fluorescent double-staining technique, angiotensin II reduced staining mismatch (indicative of intermittent blood flow) in SCCVII microvasculature from 8.1 (2.5%) of total vessels to 2.0 (1.3%) (P less than 0.001). However, a large proportion of this reduction could be attributed to volume loading. Angiotensin II reduced but did not completely eliminate the radiobiological acute hypoxia which results from intermittent tumour vessel non-perfusion. We propose that angiotensin II improves tumour microcirculatory flow distribution via its systemic actions, by elevating perfusion pressure, thereby preventing collapse and/or temporary flow stasis in tumour microvessels.
Similar articles
-
Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration.Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):785-9. doi: 10.1016/0360-3016(89)90067-9. Int J Radiat Oncol Biol Phys. 1989. PMID: 2777668
-
Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse.Br J Cancer. 1990 Dec;62(6):903-8. doi: 10.1038/bjc.1990.406. Br J Cancer. 1990. PMID: 2257217 Free PMC article.
-
Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation.Br J Cancer. 2000 Jul;83(2):225-31. doi: 10.1054/bjoc.2000.1229. Br J Cancer. 2000. PMID: 10901375 Free PMC article.
-
Radiation-induced reoxygenation in the SCCVII murine tumour: evidence for a decrease in oxygen consumption and an increase in tumour perfusion.Radiother Oncol. 1994 Jul;32(1):37-46. doi: 10.1016/0167-8140(94)90447-2. Radiother Oncol. 1994. PMID: 7938677
-
Interaction between the natriuretic effects of renal perfusion pressure and the antinatriuretic effects of angiotensin and aldosterone in control of sodium excretion.J Physiol (Paris). 1984;79(6):511-7. J Physiol (Paris). 1984. PMID: 6399318 Review.
Cited by
-
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.Nat Rev Cancer. 2008 Jun;8(6):425-37. doi: 10.1038/nrc2397. Nat Rev Cancer. 2008. PMID: 18500244 Free PMC article. Review.
-
Mild temperature hyperthermia and radiation therapy: role of tumour vascular thermotolerance and relevant physiological factors.Int J Hyperthermia. 2010;26(3):256-63. doi: 10.3109/02656730903453546. Int J Hyperthermia. 2010. PMID: 20210610 Free PMC article. Review.
-
Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.Transl Oncol. 2012 Apr;5(2):66-71. doi: 10.1593/tlo.11307. Epub 2012 Apr 1. Transl Oncol. 2012. PMID: 22496921 Free PMC article.
-
Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging.World J Surg. 1995 Nov-Dec;19(6):836-42. doi: 10.1007/BF00299780. World J Surg. 1995. PMID: 8553675 Clinical Trial.
-
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.Redox Biol. 2015 Dec;6:1-8. doi: 10.1016/j.redox.2015.07.002. Epub 2015 Jul 2. Redox Biol. 2015. PMID: 26164533 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials